Asoprisnil

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Asoprisnil
Asoprisnil.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC28H35NO4
Molar mass449.582 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Asoprisnil (INN; developmental code name J-867) is a synthetic, steroidal selective progesterone receptor modulator that was under development by Schering and TAP Pharmaceutical Products for the treatment of uterine fibroids.[1] In 2005, phase III clinical trials were discontinued due to endometrial changes in patients.[2]

See also[edit]

References[edit]

  1. ^ DeManno D, Elger W, Garg R, et al. (2003). "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids. 68 (10–13): 1019–32. doi:10.1016/j.steroids.2003.09.008. PMID 14667995.
  2. ^ Schering Interim Report Q1-3 2005